Trial Profile
A Randomized, Double Blind, Placebo-controlled Study to Evaluate the Impact of Low Doses of Nilotinib (Tasigna®) on Safety, Biomarkers and Clinical Outcomes in Subjects With Mild to Moderate Alzheimer's Disease
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Nilotinib (Primary)
- Indications Alzheimer's disease; Dementia
- Focus Adverse reactions; Biomarker
- 31 Jul 2020 Results presented at the Alzheimer's Association International Conference 2020
- 28 May 2020 Results published in the Annals of Neurology
- 12 Mar 2019 Planned End Date changed from 1 Dec 2019 to 1 Feb 2020.